CORONA Remedies Share Price
2094.30-33.50 (-1.57%)
+45.60% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | - | 17% | 17% |
| - | - | 30% | 24% |
| - | - | - | - |
| 24% | 24% | 25% | 27% |
Peer Comparison
Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
ZYDUSLIFE
CIPLA
LAURUSLABS
LUPIN
MANKIND
DRREDDY
AUROPHARMA
CORONA
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 1,901.1 | ₹456833 Cr | 37.77 | 12.07 | 62.82 | ₹11479 Cr |
| 9,157 | ₹245426 Cr | 83.91 | 34.04 | 128.41 | ₹2568 Cr |
| 4,837 | ₹187320 Cr | 85.89 | 16.72 | 97.06 | ₹2163 Cr |
| 1,129.3 | ₹113217 Cr | 25.09 | 9.42 | 62.53 | ₹5040 Cr |
| 1,380.3 | ₹112212 Cr | 33.29 | 9.77 | 57.87 | ₹3879 Cr |
| 1,846.2 | ₹101155 Cr | 92.52 | 6.8 | 29.25 | ₹889 Cr |
| 2,112.9 | ₹97626 Cr | 17.66 | 30.95 | 154.36 | ₹5333 Cr |
| 2,331.7 | ₹96859 Cr | 47.42 | 13.75 | 71.08 | ₹1913 Cr |
| 1,157.5 | ₹96406 Cr | 29.92 | 5.32 | 63.99 | ₹4196 Cr |
| 1,651.5 | ₹93614 Cr | 25.22 | 17.95 | 96.84 | ₹3505 Cr |
| 2,094.3 | ₹12993 Cr | 65.28 | 9.83 | 39.44 | ₹185 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|
| ₹422 Cr | ₹353 Cr | ₹342 Cr | ₹361 Cr | ₹347 Cr | ₹294 Cr | ₹298 Cr | ₹314 Cr |
| ₹3 Cr | ₹4 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹76 L | ₹2 Cr |
| ₹426 Cr | ₹357 Cr | ₹345 Cr | ₹363 Cr | ₹349 Cr | ₹295 Cr | ₹298 Cr | ₹316 Cr |
| ₹343 Cr | ₹301 Cr | ₹269 Cr | ₹292 Cr | ₹286 Cr | ₹250 Cr | ₹238 Cr | ₹256 Cr |
| ₹96 Cr | ₹66 Cr | ₹85 Cr | ₹81 Cr | ₹72 Cr | ₹56 Cr | ₹70 Cr | ₹69 Cr |
| ₹3 Cr | ₹1 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹3 Cr |
| ₹80 Cr | ₹54 Cr | ₹55 Cr | ₹70 Cr | ₹61 Cr | ₹43 Cr | ₹58 Cr | ₹57 Cr |
| ₹60 Cr | ₹45 Cr | ₹41 Cr | ₹52 Cr | ₹46 Cr | ₹31 Cr | ₹45 Cr | ₹43 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Secured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| — | — | — | — |
| ₹61 Cr | ₹61 Cr | ₹61 Cr | ₹61 Cr |
| ₹686 Cr | ₹545 Cr | ₹419 Cr | ₹347 Cr |
| ₹686 Cr | ₹545 Cr | ₹419 Cr | ₹347 Cr |
| ₹747 Cr | ₹606 Cr | ₹480 Cr | ₹409 Cr |
| ₹0 | ₹16 Cr | ₹67 Cr | ₹0 |
| ₹12 Cr | ₹8 Cr | ₹4 Cr | -₹4 Cr |
| ₹19 Cr | ₹21 Cr | ₹23 Cr | ₹24 Cr |
| ₹66 Cr | ₹39 Cr | ₹32 Cr | ₹25 Cr |
| ₹97 Cr | ₹84 Cr | ₹126 Cr | ₹45 Cr |
| — | — | — | — |
| ₹147 Cr | ₹144 Cr | ₹114 Cr | ₹94 Cr |
| ₹46 Cr | ₹52 Cr | ₹50 Cr | ₹18 Cr |
| ₹127 Cr | ₹11 Cr | ₹31 Cr | ₹2 Cr |
| ₹135 Cr | ₹121 Cr | ₹73 Cr | ₹94 Cr |
| ₹455 Cr | ₹327 Cr | ₹269 Cr | ₹209 Cr |
| ₹1299 Cr | ₹1017 Cr | ₹875 Cr | ₹663 Cr |
| ₹1 Cr | ₹0 | ₹0 | ₹0 |
| ₹143 Cr | ₹63 Cr | ₹134 Cr | ₹2 Cr |
| — | — | — | — |
| ₹724 Cr | ₹503 Cr | ₹483 Cr | ₹256 Cr |
| ₹170 Cr | ₹133 Cr | ₹99 Cr | ₹72 Cr |
| ₹554 Cr | ₹370 Cr | ₹384 Cr | ₹185 Cr |
| ₹143 Cr | ₹186 Cr | ₹121 Cr | ₹65 Cr |
| ₹26 Cr | ₹26 Cr | ₹26 Cr | ₹26 Cr |
| ₹26 Cr | ₹26 Cr | ₹26 Cr | ₹26 Cr |
| ₹5 Cr | ₹9 Cr | ₹9 Cr | ₹10 Cr |
| ₹129 Cr | ₹10 L | ₹2 Cr | ₹15 Cr |
| ₹857 Cr | ₹591 Cr | ₹541 Cr | ₹299 Cr |
| — | — | — | — |
| ₹0 | ₹0 | ₹0 | ₹6 Cr |
| ₹125 Cr | ₹129 Cr | ₹98 Cr | ₹105 Cr |
| ₹146 Cr | ₹118 Cr | ₹100 Cr | ₹87 Cr |
| ₹44 Cr | ₹69 Cr | ₹70 Cr | ₹77 Cr |
| ₹2 Cr | ₹7 Cr | ₹4 Cr | ₹3 Cr |
| ₹125 Cr | ₹102 Cr | ₹63 Cr | ₹85 Cr |
| ₹442 Cr | ₹426 Cr | ₹335 Cr | ₹363 Cr |
| -₹13 Cr | ₹99 Cr | ₹66 Cr | ₹154 Cr |
| ₹1299 Cr | ₹1017 Cr | ₹875 Cr | ₹663 Cr |
| ₹122 | ₹99 | ₹79 | ₹67 |
| ₹122 | ₹99 | ₹79 | ₹67 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Effect of Foreign Exchange Fluctuations
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| ₹240 Cr | ₹199 Cr | ₹118 Cr | ₹111 Cr |
| ₹44 Cr | ₹52 Cr | ₹47 Cr | ₹23 Cr |
| -₹6 Cr | -₹17 Cr | ₹9 Cr | -₹5 Cr |
| ₹279 Cr | ₹234 Cr | ₹175 Cr | ₹129 Cr |
| ₹229 Cr | ₹190 Cr | ₹157 Cr | ₹103 Cr |
| -₹256 Cr | -₹84 Cr | -₹267 Cr | -₹50 Cr |
| ₹25 Cr | -₹107 Cr | ₹99 Cr | -₹45 Cr |
| -₹1 Cr | ₹6 L | -₹11 Cr | ₹8 Cr |
| ₹3 Cr | ₹3 Cr | ₹14 Cr | ₹7 Cr |
| ₹0 | ₹0 | ₹20,000 | -₹4 L |
| ₹2 Cr | ₹3 Cr | ₹3 Cr | ₹14 Cr |
Fundamental Ratios
Consolidated
Standalone
No results found